New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For RHHBY;AZN;NVS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 13, 2014
07:03 EDTAZNAstraZeneca initiates development program for Brilinta reversal agent
Subscribe for More Information
05:34 EDTAZNAstraZeneca, Isis Pharmaceuticals to co-develop oligonucleotide delivery methods
Subscribe for More Information
November 12, 2014
11:17 EDTNVS, RHHBY, AZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:18 EDTNVSUBS to hold a conference
Subscribe for More Information
07:58 EDTNVSGenVec expects 2014 cash burn between $6M-$7M from Novartis collaboration
Subscribe for More Information
07:35 EDTAZNAdvaxis submits IND application for ADXS-HPV Phase 1/2 study, MEDI4736
Advaxis (ADXS) announced that the company has submitted an Investigational New Drug application, or IND, to the FDA to conduct a Phase 1/2 study of ADXS-HPV alone or in combination with MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, for the treatment of advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. This follows the press release issued in July announcing the clinical trial collaboration between Advaxis and MedImmune, the global biologics research and development arm of AstraZeneca (AZN).
07:22 EDTRHHBYAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
November 11, 2014
16:14 EDTNVSLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
16:05 EDTAZNAmgen, AstraZeneca say Phase 3 brodalumab study met endpoints
Subscribe for More Information
16:01 EDTNVSQIAGEN enters master collaboration agreement with Novartis
Subscribe for More Information
15:43 EDTRHHBY, NVS, AZNLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
16:07 EDTRHHBY, NVSUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:57 EDTNVSWorldwide Business Research to hold a conference
ProcureCon for Digital & Marketing Services 2014 is being held in San Antonio on November 11-13.
November 6, 2014
12:48 EDTNVSNovartis: FDA Advisory Committee does not recommend LBH589
Novartis announced that the US FDA's Oncologic Drugs Advisory Committe did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated multiple myeloma when used in combination with bortezomib and dexamethasone. The Committee's vote will be considered by the FDA in its review of the LBH589 new drug application, but the FDA is not bound to follow the Committee's guidance. The final decision regarding US approval is made by the FDA. "We are disappointed by this voting outcome and believe the results from our clinical trials provide strong evidence to support LBH589 as a potential first- in-class treatment option for multiple myeloma, a cancer where an unmet patient need exists," said Bruno Strigini, President, Novartis Oncology. "We will continue to work with the FDA as it completes its review of the US application."
07:16 EDTNVSFDA Oncologic Drugs Advisory Committee to hold a meeting
Subscribe for More Information
06:35 EDTAZNAstraZeneca CEO says tax revisions cripple new Pfizer offer, Reuters says
Subscribe for More Information
05:51 EDTAZNAstraZeneca targets 2015 EPS to be no less than low end of 2014 range
AstraZeneca said, "For 2015, the Company plans to continue to selectively invest in its growth platforms and accelerating pipeline while managing overall costs. Assuming current exchange rates, the Company is targeting Core EPS for 2015 to be no less than the lower end of the range of the upgraded guidance for Core EPS for 2014 at actual exchange rates. Guidance for 2015 is expected to be provided with 2014 results on 5 February 2015."
05:50 EDTAZNAstraZeneca raises 2014 revenue growth outlook to low single digits at CER
AstraZeneca said 2014 revenue is now expected to increase in low single digits at CER, an upgrade to its previous guidance for revenue to be in line with 2013 at CER. The guidance assumes no U.S. Nexium generic in 2014. It added, "In light of the increase in revenue expectations for the year, the Company is accelerating its investments in its growth platforms and expanding pipeline. Core EPS for 2014 is now expected to decrease at around 10% at CER; better than anticipated in previous guidance. In addition, Core EPS for 2014 at actual exchange rates is expected to be impacted negatively by currency by around 5%, assuming current exchange rates."
05:49 EDTAZNAstraZeneca reports Q3 core EPS $1.05, consensus $1.04
Subscribe for More Information
05:37 EDTAZNAegerion acquires Myalept from AstraZeneca for $325M
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use